HCAT Form 144: Proposed Sale of 2,854 Shares Valued $9,597
Health Catalyst, Inc. (HCAT) Form 144 notice reports a proposed sale of 2,854 common shares with an aggregate market value of $9,597.15, to be sold through Morgan Stanley Smith Barney LLC on 09/02/2025 on NASDAQ.
Rhea-AI Filing Summary
Health Catalyst, Inc. (HCAT) Form 144 notice reports a proposed sale of 2,854 common shares with an aggregate market value of $9,597.15, to be sold through Morgan Stanley Smith Barney LLC on 09/02/2025 on NASDAQ. The shares were acquired on 09/02/2025 as restricted stock from Health Catalyst, Inc. and were granted as compensation. The filer represents they are not aware of undisclosed material adverse information. The filing also discloses a prior sale by Linda Llewelyn of 2,965 restricted shares on 06/02/2025 for gross proceeds of $10,777.18.
Positive
- Filer provided required Rule 144 details: class, quantity, broker, exchange, acquisition date, and nature of acquisition (compensation).
- Planned sale routed through a registered broker (Morgan Stanley Smith Barney LLC) and lists NASDAQ as the market.
Negative
- Insider sold restricted shares recently: 2,965 shares sold on 06/02/2025 for gross proceeds of $10,777.18, which is disclosed in the filing.
Insights
TL;DR Form 144 notifies a planned Rule 144 sale of 2,854 restricted shares acquired as compensation; filing appears procedural and compliant.
The filing documents a proposed sale under Rule 144 through a registered broker, names the broker and exchange, and states acquisition and payment details explicitly: restricted stock acquired and paid as compensation on the same date listed. It includes a recent related sale by the same person in June 2025. From a compliance perspective, the submission contains the core elements required for a Rule 144 notice: class, quantity, acquisition details, sale timing, broker, and a representation about undisclosed material information.
TL;DR Transaction size is modest and routine; filing signals a planned insider disposition via broker on NASDAQ.
The notice shows a small, single-party disposition (2,854 shares, ~$9.6k) to be executed on a specified date via Morgan Stanley Smith Barney. The shares were acquired as restricted compensation on the same date listed and are being sold under Rule 144. A prior sale of 2,965 restricted shares generated ~$10.8k in June 2025. The amounts disclosed are small in absolute terms relative to typical public-company float, suggesting limited market impact; all material transaction details are provided in the form.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Form 144 filed for HCAT disclose?
Which broker and exchange are involved in the proposed sale?
Does the filer attest to possession of material nonpublic information?
AI-generated analysis. How Rhea-AI works. Not financial advice.